Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy

Details 詳細情報について

• CRID

  1361699994573471744

• DOI

  10.1093/annonc/mdr125

• ISSN

  09237534

• Web Site

  https://api.elsevier.com/content/article/PII:S092375341934387X?httpAccept=text/xml

  https://api.elsevier.com/content/article/PII:S092375341934387X?httpAccept=text/plain

  http://academic.oup.com/annonc/article-pdf/23/2/388/550965/mdr125.pdf

• Data Source

  • Crossref